Civitas considers options as inhaled levodopa curtails dyskinesia
This article was originally published in Scrip
Executive Summary
Civitas Therapeutics is mulling its Phase III clinical trial design and financing options based on the success of a Phase IIb trial that showed the company's inhaled levodopa, CVT-301, provided rapid onset and relief from dyskinesia in patients with Parkinson's disease.
You may also be interested in...
Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing
Acorda's $525m purchase of Civitas in 2014 is now set to bear fruit, with new Phase III data for an inhaled formulation of levodopa, the main attraction of the deal, looking strong enough both to warrant approval filings and please payors.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.